Spring Investor Conference Financial Performance 2003

Size: px
Start display at page:

Download "Spring Investor Conference Financial Performance 2003"

Transcription

1 Spring Investor Conference Financial Performance 2003 Klaus Kühn, CFO Safe Harbor This presentation contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

2 Financial Highlights 2003 Net special items underlying Non-operating result Pre-tax income (loss) After-tax income (loss) Net income (loss) Earnings per share ( ) Q4 7,121 (2,753) (2,774) 21 (103) (232) (2,985) (1,955) (1,952) (2.67) % yoy ,567 (2,585) 1,382 3,532 (791) (1,994) (1,349) (1,361) 3, (1.86) % yoy Reconciliation of Basis (197) Hedging gains 2) (net) New definition of special items 1) Reported 2002 underlying cont. Adjusted 2002 underlying cont. 1) Mainly gains from BCS product disposals 2) In 2003 reallocated from financial result to

3 2003 Hampered by High Special Charges + 1,382 (1,927) Total Special items (2,585) 2003 before special items Impairment losses, valuation (508) adjustments Restructuring expenses, other asset write-downs (619) Other special items Portfolio changes 2003 Hampered by High Special Charges + 1, before special items Polymers ( 1,134) Chemicals (476) HealthCare (317) Impairment losses, valuation (508) adjustments Restructuring expenses, other asset write-downs Impairment losses and valuation adjustments Polymers: Plastics/Rubber: (463) Summe Polyurethanes/Coatings/Fibers: Sondereinflüsse (671) (619) Other special items Portfolio changes

4 2003 Hampered by High Special Charges + 1, before special items Polymers ( 1,134) Chemicals (476) HealthCare (317) Impairment losses, valuation (508) adjustments Restructuring expenses, other asset write-downs Impairment losses and valuation adjustments Chemicals: Fine Chemicals: (286) Textile Chemicals Summe Paper Chemicals Sondereinflüsse (190) Inorganic Pigments (619) Other special items Portfolio changes 2003 Hampered by High Special Charges + 1, before special items Polymers ( 1,134) Chemicals (476) HealthCare (317) Impairment losses, valuation (508) adjustments Restructuring expenses, other asset write-downs Impairment losses and valuation adjustments HealthCare: Summe Plasma Business: Sondereinflüsse (317) (619) Other special items Portfolio changes

5 2003 Hampered by High Special Charges + 1,382 (1,927) Restructuring and other asset writedowns: Restructuring CropScience: Summe (102) Restructuring Polymers: Sondereinflüsse (135) Closure Kyoto: (119) Write-down SAP System: (100) Others: (52) 2003 before special items Impairment losses, valuation (508) adjustments Restructuring expenses, other asset write-downs (619) Other special items Portfolio changes 2003 Hampered by High Special Charges + 1,382 (1,927) Summe Other special items: Sondereinflüsse Accounting measures Baycol: (300) Senior part-time working: (209) Others: (110) 2003 before special items Impairment losses, valuation (508) adjustments Restructuring expenses, other asset write-downs (619) Other special items Portfolio changes

6 2003 Hampered by High Special Charges + 1,382 (1,927) Total Special items (2,585) 2003 before special items Impairment losses, valuation (508) adjustments Restructuring expenses, other asset write-downs (619) Other special items Portfolio changes Financial Highlights in Q4 Net special items underlying Non-operating result Pre-tax income (loss) After-tax income (loss) Net income (loss) Earnings per share ( ) 7,428 (340) (281) (59) 761 (300) (640) (418) (412) 829 1,679 (0.56) 7,121 (2,753) (2,774) 21 (103) (232) (2,985) (1,955) (1,952) (2.67) yoy ,413 2, ,345-1,537-1,

7 Components of Q4 Trend Q4'02 Q4'03 % yoy + Acquisitions / Divestitures - Currencies -Prices + Volumes 7,428 (265) (525) (74) 557 7, CropScience (net) Household Ins., CC Polymer Latex, PO Organic Pigm., CH Walothen, CH Others (155) (42) (42) (9) (10) (7) Financial Highlights in Q4 Net special items underlying Non-operating result Pre-tax income (loss) After-tax income (loss) Net income (loss) Earnings per share ( ) 7,428 (340) (281) (59) 761 (300) (640) (418) (412) 829 1,679 (0.56) 7,121 (2,753) (2,774) 21 (103) (232) (2,985) (1,955) (1,952) (2.67) yoy ,413 2, ,345-1,537-1,

8 HealthCare Pharma / Biological Products in LC 1,227 1, (256) (434) (378) (810) Special Items (364) (785) Underlying (14) (25) (222) (298) 238 (203) HealthCare Consumer Care / Diagnostics in LC Special items 239 (47) Underlying

9 HealthCare Animal Health in LC Special Items (11) 20 Underlying CropScience in LC 1,435 1, Crop Protection 1,256 1, Insecticides Fungicides Herbicides Seed Treatment Others (Transitional ACS) (40) 5 Environmental Science BioScience

10 CropScience (55) (18) Special items Underlying (125) Polymers Plastics / Rubber in LC 1,259 1, (25) (50) (625) Special items (35) 577 Underlying (15) (48)

11 Polymers PUR / Coatings / Fibers in LC 1,292 1, (145) (687) Special items (194) (737) Underlying Chemicals in LC (1) 7 (552) Special Items 13 (528) Underlying (6) (24)

12 Non-Operating Result % Non-operating result (654) (791) Income (exp.) from affiliated companies - net 223 (93) Interest expense - net (449) (353) Interest portion of provisions (296) (281) Exchange losses - net (5) (31) Miscellaneous - net (127) (33) Income (loss) before income-taxes 956 (1,994) Taxes 2003 Income taxes* Germany Other countries Effective tax rate (%) Other taxes (45) 152 (11.2) (221) (32.3) (303) * including deferred taxes

13 Balance Sheet Structure 2003 billion 37.4 (10%) 37.4 (10%) Property, Plant, Equipment 9.9 (-20%) 12.2 (-20%) Stockholders equity Intangibles Investments 6.5 (-27%) 1.8 (-19%) 8.9 (+6%) Provisions Trade a/c receiv. + inventories 11.0 (-8%) 4.7 (-1%) Remaining liabilities Other current assets 6.7 (+34%) 9.4 (-7%) Financial obligations Excluding minority interests, deferred taxes and deferred charges/income Free Cash Flow 2003 FY 2002 FY ,085 3,244 +/- Changes in working capital = 850 1, ,373 4, ,293 - Capital expenditures (638) (469) (2,239) (1,653) = Free operating cash flow 1, ,219 1,640 - Interest, dividends (81) (98) (964) (1,081) = Free cash flow , /- Acquisitions / divestments 1, (4,759) 1,830 = Free cash flow after acquis./divest. 1, (3,504) 2,389 Changes due to cash payments - Derivatives, currencies, other (1,985) (597) (696) (282) 3,504 (1,180) (2,389) (520) Net debt (balance sheet) (2,582) (978) 2,324 (2,909)

14 Dividend 2003 Earnings per share Cash flow per share

Lehman Conference, April 2003

Lehman Conference, April 2003 Lehman Conference, April 2003 Klaus Kühn, CFO of Bayer AG Safe Harbor This presentation contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various

More information

Spring Investor Conference Werner Wenning CFO and Member of the Board

Spring Investor Conference Werner Wenning CFO and Member of the Board Spring Investor Conference 2002 Werner Wenning CFO and Member of the Board Safe Harbour This presentation contains forward-looking statements based on current assumptions and forecasts made by Bayer Group

More information

Investor Conference. London, August 6, First Half 2003 Results

Investor Conference. London, August 6, First Half 2003 Results Investor Conference London, August 6, 23 First Half 23 Results Safe Harbor This presentation contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management.

More information

Investor Handout Q Results

Investor Handout Q Results Investor Handout Q3 Results Safe Harbor This presentation contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks,

More information

Investor Handout Q Results

Investor Handout Q Results Investor Handout Q3 2002 Results Table Of Contents Safe Harbour 1 Performance 2 A Far-Reaching Transformation 12 Strategic Priorities 19 Financials 29 2 Safe Harbor This presentation contains forward-looking

More information

Stockholders Newsletter

Stockholders Newsletter Stockholders Newsletter 2002 Interim Report for the First Three Quarters Bayer Group Highlights Performance by Business Area Performance by Region Liquidity and capital resources Earnings performance Asset

More information

Stockholders Newsletter

Stockholders Newsletter Stockholders Newsletter 2003 Interim Report for the First Quarter Bayer Group Highlights Performance by Business Area Performance by Region Liquidity and capital resources Earnings performance Asset and

More information

Stockholders Newsletter

Stockholders Newsletter Stockholders Newsletter 2003 Interim Report for the First Half Bayer Group Highlights Performance by Business Area Performance by Region Liquidity and capital resources Earnings performance Asset and capital

More information

Stockholders Newsletter

Stockholders Newsletter Stockholders Newsletter 2003 Interim Report for the First Three Quarters Bayer Group Highlights Chairman s Letter General Business Development Performance by Business Area Performance by Region Liquidity

More information

Investor Conference Call

Investor Conference Call Investor Conference Call Q3 2014 Results October 30, 2014 / Marijn Dekkers, CEO Page 1 Q3 2014 Investor Conference Call Marijn Dekkers Disclaimer This presentation may contain forward-looking statements

More information

EASTMAN CHEMICAL COMPANY EMN January 26, :30 PM EDT. Table of Contents. TABLE 1 Statements of Earnings 1. TABLE 2 Other Sales Information 2-3

EASTMAN CHEMICAL COMPANY EMN January 26, :30 PM EDT. Table of Contents. TABLE 1 Statements of Earnings 1. TABLE 2 Other Sales Information 2-3 FINANCIAL INFORMATION January 26, 2006 For use in the Eastman Chemical Company Conference Call at 8:00 AM (EDT), January 27, 2006. Table of Contents Item Page TABLE 1 Statements of 1 TABLE 2 Other Sales

More information

Investor Conference Call Q Results

Investor Conference Call Q Results Science For A Better Life Investor Conference Call Q1 2009 Results Werner Wenning, CEO April 29 2009 Q1 2009 Investor Conference Call Werner Wenning Disclaimer This presentation may contain forward-looking

More information

Q Analyst and Investor Briefing March 3, 2009

Q Analyst and Investor Briefing March 3, 2009 Q4 2008 Analyst and Investor Briefing March 3, 2009 Sales declined by 1.5% to 7,923m (Q4 07: 8,040m); Volume -5.7%, price +1.7%, currency +2.0%, portfolio +0.6%. Portfolio and Fx adj. sales dropped by

More information

Q Analyst and Investor Briefing February 26, 2010

Q Analyst and Investor Briefing February 26, 2010 Q4 2009 Analyst and Investor Briefing February 26, 2010 Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Sales declined by 0.6% to 7,872m (Q4 08: 7,923m); volume 8.2%, price

More information

Q Analyst and Investor Briefing April 29, 2009

Q Analyst and Investor Briefing April 29, 2009 Q1 2009 Analyst and Investor Briefing April 29, 2009 Sales declined by 7.5% to 7,895m (Q1 08: 8,536m); Volume -9.4%, price -0.3%, currency +1.9%, portfolio +0.3%. Portfolio and Fx adj. sales dropped by

More information

Q Analyst and Investor Briefing July 31, 2012

Q Analyst and Investor Briefing July 31, 2012 Q2 212 Analyst and Investor Briefing July 31, 212 Bayer raises guidance for the full year Strong business performance in the second quarter of 212 Record sales 1.2 billion (+5.% Fx and portfolio adjusted)

More information

of 5 01/08/ :58

of 5 01/08/ :58 July 31, 2012 Strong business performance in the second quarter of 2012: Sales increased by 10.0 percent to a record EUR 10,177 million / CropScience and HealthCare sustained strong momentum, MaterialScience

More information

Investor Conference Call

Investor Conference Call Investor Conference Call FY/Q4 2015 Results February 25, 2016 / Marijn Dekkers, CEO Page 1 Q4/FY 2015 Investor Conference Call Marijn Dekkers Disclaimer This presentation may contain forward-looking statements

More information

News Release. Bayer: sales and EBIT at record levels. Financial and innovation targets for 2011 achieved

News Release. Bayer: sales and EBIT at record levels. Financial and innovation targets for 2011 achieved News Release Bayer AG Communications 51368 Leverkusen Germany Tel. +49 214 30-1 www.press.bayer.com Financial and innovation targets for 2011 achieved Bayer: sales and EBIT at record levels Sales increase

More information

Bayer increases sales and earnings in the second quarter

Bayer increases sales and earnings in the second quarter News Release Bayer AG Communications 51368 Leverkusen Germany Tel. +49 214 30-1 www.press.bayer.com MaterialScience leaves the crisis behind Bayer increases sales and earnings in the second quarter Sales

More information

Non-Deal Debt Roadshow

Non-Deal Debt Roadshow Science For A Better Life Non-Deal Debt Roadshow Johannes M. Dietsch, Finance Director December 2007 Bayer Non-Deal Debt Roadshow December 2007 Disclaimer This presentation contains forward-looking statements

More information

Q Analyst and Investor Briefing October 27, 2009

Q Analyst and Investor Briefing October 27, 2009 Q3 2009 Analyst and Investor Briefing October 27, 2009 Sales declined by 7.0% to 7,392m (Q3 08: 7,948m); volume -2.8%, price -4.4%, currency +0.6%, portfolio -0.4%. Portfolio and Fx adj. sales dropped

More information

Information for Stockholders. Interim Report for the First Quarter

Information for Stockholders. Interim Report for the First Quarter 2000 Information for Stockholders Interim Report for the First Quarter Information for Stockholders Excellent start to the year Pre-tax income up 31 percent 2 Bayer Information for Stockholders Sales (

More information

CropScience Analyst & Investor Days

CropScience Analyst & Investor Days CropScience Analyst & Investor Days September 5 & 6, 2005 Lyon, France CropScience Analyst & Investor Days Efficiency Improvement and Business Excellence September 5-6, 2005 Lyon, France Dr. Dirk Suwelack

More information

Investor Handout. Financials. Strategy R & D

Investor Handout. Financials. Strategy R & D Investor Handout Financials Strategy R & D Sustained increase in the company s value Focus on creating value and improving profitability State-of-the-art portfolio management system Expansion of life science

More information

Investor Handout. Financials. Strategy R & D. Investor Handout Spring 2001

Investor Handout. Financials. Strategy R & D. Investor Handout Spring 2001 Investor Handout Financials Strategy R & D 1 Corporate Objectives Continuously increase corporate value Achieve above average return on capital 26 34 41 Market capitalization (3 billions) 14 949 1,022

More information

Investor Handout 1st Half The Transformation has begun 1st Half 2002 Results

Investor Handout 1st Half The Transformation has begun 1st Half 2002 Results The Transformation has begun 1st Half 2002 Results Safe Harbor This presentation contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known

More information

News Release. Bayer: operating performance on track. Financial News Conference on fiscal 2010:

News Release. Bayer: operating performance on track. Financial News Conference on fiscal 2010: News Release Bayer AG Communications 51368 Leverkusen Germany Tel. +49 214 30-1 www.press.bayer.com Financial News Conference on fiscal 2010: Bayer: operating performance on track Group targets achieved

More information

July 23, 2013 Media Contact: Michael Hanretta WILMINGTON, Del Investor Contact:

July 23, 2013 Media Contact: Michael Hanretta WILMINGTON, Del Investor Contact: July 23, 2013 Media Contact: Michael Hanretta WILMINGTON, Del. 302-774-4005 michael.j.hanretta@dupont.com Investor Contact: 302-774-4994 DuPont Delivers 2Q 2013 Operating EPS of $1.28 Agriculture Sales

More information

Spring Investor Conference 2003

Spring Investor Conference 2003 Spring Investor Conference 2003 Rolf Classon, Bayer HealthCare Safe Harbor This presentation contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management.

More information

Q Analyst and Investor Briefing July 28, 2011

Q Analyst and Investor Briefing July 28, 2011 Q2 211 Analyst and Investor Briefing July 28, 211 Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Group sales at 9,252 million, up 5.4% (portfolio and currency adjusted) Price

More information

Q Analyst and Investor Briefing October 28, 2010

Q Analyst and Investor Briefing October 28, 2010 Q3 21 Analyst and Investor Briefing October 28, 21 Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Further growth in Group sales and underlying EBITDA mainly driven by business

More information

Investor News. Bayer: strong business momentum continues and portfolio transformation underway. Fiscal 2014:

Investor News. Bayer: strong business momentum continues and portfolio transformation underway. Fiscal 2014: Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Fiscal 2014: Bayer: strong business momentum continues and portfolio transformation underway Group portfolio to

More information

The New Bayer. more highly focused more flexible more transparent more strategic options more entrepreneurial responsibility

The New Bayer. more highly focused more flexible more transparent more strategic options more entrepreneurial responsibility 1 The New Bayer more highly focused more flexible more transparent more strategic options more entrepreneurial responsibility 2 Transforming Bayer into a Holding Structure Bayer AG Board of Management

More information

Investor Conference Call

Investor Conference Call Investor Conference Call Q3 2017 Results October 26, 2017 / Werner Baumann, CEO Cautionary Statements Regarding Forward- Looking Information Certain statements contained in this communication may constitute

More information

LANXESS FY/Q Financial Summary for Investors and Analysts

LANXESS FY/Q Financial Summary for Investors and Analysts LANXESS FY/Q4 2016 Financial Summary for Investors and Analysts Summary FY 2016 Transformation gains traction Significant strategic evolution of the company with the establishment of ARLANXEO Integration

More information

January 28, 2014 Media Contact: Patty Seif WILMINGTON, Del Investor Contact:

January 28, 2014 Media Contact: Patty Seif WILMINGTON, Del Investor Contact: January 28, 2014 Media Contact: Patty Seif WILMINGTON, Del. 302-774-4482 patricia.r.seif@dupont.com Investor Contact: 302-774-4994 DuPont Reports 4Q and Full-Year 2013 Operating EPS of $.59 and $3.88;

More information

Value across the cycle

Value across the cycle Dr. Jürgen Hambrecht, CEO Dr. Kurt Bock, CFO February 21, 2008 Looking with confidence to 2008 Value across the cycle BASF posts new records Financial performance 2007 Sales up by 10% to 58 billion EBIT

More information

Investor Release. BASF confirms outlook for 2012 despite growing economic risks

Investor Release. BASF confirms outlook for 2012 despite growing economic risks Investor Release BASF confirms outlook for 2012 despite growing economic risks 2 nd quarter 2012: - Sales up 6% and EBIT before special items up 11% compared with previous year s quarter - Strong business

More information

Third Quarter Results 2005

Third Quarter Results 2005 Science For A Better Life Company Presentation Third Quarter Results 25 Forward Looking Statements This presentation contains forward-looking statements based on current assumptions and forecasts made

More information

LANXESS AG Executing on Strategy and Operations

LANXESS AG Executing on Strategy and Operations LANXESS AG Executing on Strategy and Operations 17 th Annual Citigroup Chemicals Conference New York, December 5 th 6 th, 2006 Matthias Zachert, CFO Conference 2006 Chart-No. 1 Safe harbour statement This

More information

Bayer Polymers Top League Player In A Changing Market

Bayer Polymers Top League Player In A Changing Market Bayer Polymers Top League Player In A Changing Market Hagen Noerenberg Head of Bayer Polymers March 2002 Safe Harbor This presentation contains forward-looking statements based on current assumptions and

More information

October 25, 2011 Media Contact: Michael Hanretta WILMINGTON, Del Investor Contact:

October 25, 2011 Media Contact: Michael Hanretta WILMINGTON, Del Investor Contact: October 25, 2011 Media Contact: Michael Hanretta WILMINGTON, Del. 302-774-4005 michael.j.hanretta@usa.dupont.com Investor Contact: 302-774-4994 DuPont Delivers Strong EPS Growth on 32% Higher Sales for

More information

Investor Conference Call

Investor Conference Call Investor Conference Call FY/Q4 2014 Results February 26, 2015 / Marijn Dekkers, CEO Disclaimer This presentation may contain forward-looking statements based on current assumptions and forecasts made by

More information

Investor News. Another record year for Bayer. Fiscal 2015:

Investor News. Another record year for Bayer. Fiscal 2015: Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Fiscal 2015: Another record year for Bayer Focus on the Life Sciences following the successful stock market flotation

More information

Analyst Conference Call Full Year Ludwigshafen, February 27, 2018

Analyst Conference Call Full Year Ludwigshafen, February 27, 2018 Analyst Conference Call Full Year 217 Ludwigshafen, February 27, 218 Cautionary note regarding forward-looking statements This presentation contains forward-looking statements. These statements are based

More information

Stockholders Newsletter 2004 Interim Report for the Third Quarter

Stockholders Newsletter 2004 Interim Report for the Third Quarter Stockholders Newsletter 2004 Interim Report for the Third Quarter TABLE OF CONTENTS Bayer Group Key Data General Business Development Sales and Earnings Subsequent Events Outlook Performance by Region

More information

Stockholders Newsletter

Stockholders Newsletter k Cover Picture Stockholders Newsletter FINANCIAL REPORT AS OF JUNE 30, quarter: Bayer robust in a difficult environment Contents INTERIM GROUP MANAGEMENT REPORT AS OF JUNE 30, k Bayer Group Key Data...3

More information

LANXESS Q Financial Summary for Investors and Analysts

LANXESS Q Financial Summary for Investors and Analysts LANXESS Q2 2007 Financial Summary for Investors and Analysts EBITDA pre exceptionals rises by 5.0% EBITDA margin pre exceptionals at 12.2% compared to 11.5% EBIT pre exceptionals increases by 9.4% Sales

More information

DANAHER CORPORATION RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES. Three-Month Period Ending

DANAHER CORPORATION RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES. Three-Month Period Ending RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES Adjusted Diluted Net Earnings Per Share from Continuing Operations Diluted Net Earnings Per Share from Continuing Operations (GAAP) Three-Month Period

More information

July 22, 2014 Media Contact: Dan Turner WILMINGTON, Del Investor Contact:

July 22, 2014 Media Contact: Dan Turner WILMINGTON, Del Investor Contact: July 22, 2014 Media Contact: Dan Turner WILMINGTON, Del. 302-774-4005 daniel.a.turner@dupont.com Investor Contact: 302-774-4994 DuPont Reports Q2 Operating Earnings Per Share of $1.17; Reaffirms Updated

More information

Brooks Automation, Inc. Financial Results Conference Call

Brooks Automation, Inc. Financial Results Conference Call Brooks Automation, Inc. 1st Quarter Fiscal2014 Financial Results Conference Call February 6, 2014 Safe Harbor Statement Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of

More information

AGILENT TECHNOLOGIES, INC. CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (In millions, except per share amounts) (Unaudited)

AGILENT TECHNOLOGIES, INC. CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (In millions, except per share amounts) (Unaudited) CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (In millions, except per share amounts) Twelve Months Ended October 31, Percent 2002 2001 Inc/(Dec) Orders $ 6,013 $ 6,414 (6%) Net revenue $ 6,010 $ 8,396

More information

Financial Report. Bayer: excellent start to as of March 31,

Financial Report. Bayer: excellent start to as of March 31, Financial Report as of March 31, Bayer: excellent start to R Bayer Group Key Data 2 Interim Group Management Report as of March 31, R Overview of Sales, Earnings and Financial Position 4 R Future Perspectives

More information

Kurt Bock, CFO UBS Best of Germany Conference New York, September 17, 2009 Tackling the challenges ahead

Kurt Bock, CFO UBS Best of Germany Conference New York, September 17, 2009 Tackling the challenges ahead Kurt Bock, CFO UBS Best of Germany Conference New York, September 17, 2009 Tackling the challenges ahead 1 Sep 2009 1 Robust performance in difficult environment 2 Managing the downturn 3 Clear priorities

More information

Quarterly Statement 1st Quarter 2018

Quarterly Statement 1st Quarter 2018 Quarterly Statement st Quarter 208 BASF Group posts earnings growth in first quarter of 208 Sales down % to 6.6 billion due to currency effects EBIT before special items increased by 2% to 2.5 billion

More information

BASF 1 st Quarter 2014 Analyst Conference Call May 2, 2014, 8:30 a.m. (CEST), Mannheim

BASF 1 st Quarter 2014 Analyst Conference Call May 2, 2014, 8:30 a.m. (CEST), Mannheim S BASF 1 st Quarter 2014 Analyst Conference Call May 2, 2014, 8:30 a.m. (CEST), Mannheim First Quarter 2014 Financial highlights May 2, 2014 Good start to the year in chemicals business, oil and gas business

More information

Price: +4% Volume: +1% FX: 0% Portfolio: +0% Δ Q Q Comments. Jun ,633 m

Price: +4% Volume: +1% FX: 0% Portfolio: +0% Δ Q Q Comments. Jun ,633 m Q3 2018 Delivering despite challenging environment Financial Summary for Investors and Analysts Q3 2018 Overview of LANXESS Group Price: +4% Volume: +1% FX: 0% Portfolio: +0% Δ Q3 2018 Q3 2017 Comments

More information

Third-quarter sales and EBIT bsi down in a difficult economic environment

Third-quarter sales and EBIT bsi down in a difficult economic environment Third Quarter 2015 Financial highlights October 27, 2015 Wolfgang Budde 150 years Third-quarter sales and EBIT bsi down in a difficult economic environment Cautionary note regarding forward-looking statements

More information

DANAHER CORPORATION RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES. Three-Month (0.02) (0.02) Pretax gain on sales of investments D,E D (0.

DANAHER CORPORATION RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES. Three-Month (0.02) (0.02) Pretax gain on sales of investments D,E D (0. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES Adjusted Diluted Net Earnings Per Share from Continuing Operations Diluted Net Earnings Per Share from Continuing Operations (GAAP) Three-Month Period

More information

Gratifying sales and earnings increases

Gratifying sales and earnings increases Stockholders Newsletter Interim Report as of September 30, Schering acquisition provides additional boost to Bayer s business Gratifying sales and earnings increases For direct access to a chapter, simply

More information

Investor Handout. Roadshow California

Investor Handout. Roadshow California Investor Handout Roadshow California July 2012 Science For A Better Life This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup

More information

BASF Analyst Conference Call FY 2015

BASF Analyst Conference Call FY 2015 BASF Analyst Conference Call FY 2015 February 26, 2016, 13:00 (CET) Ludwigshafen, Germany Analyst Conference Call Script (Long-Version) Kurt Bock, CEO Hans-Ulrich Engel, CFO The spoken word applies. Page

More information

Price: +5% Volume: +1% FX: -4% Portfolio: +6% Q Q Comments. Net Income >100% 126 m 3 m EPS includes 50% contribution of ARLANXEO

Price: +5% Volume: +1% FX: -4% Portfolio: +6% Q Q Comments. Net Income >100% 126 m 3 m EPS includes 50% contribution of ARLANXEO Q2 2018 Continued execution Financial Summary for Investors and Analysts Q2 2018 Overview of LANXESS Group Price: +5% Volume: +1% FX: -4% Portfolio: +6% Q2 2018 Q2 2017 Comments Sales +7% 1,829 m 1,712

More information

DOWDUPONT INC. (Exact name of registrant as specified in its charter)

DOWDUPONT INC. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

Ludwigshafen, February 26, 2016

Ludwigshafen, February 26, 2016 Ludwigshafen, February 26, 216 Analyst Conference Call FY215 Cautionary note regarding forward-looking statements This presentation may contain forward-looking statements that are subject to risks and

More information

Wells Fargo Securities Industrial & Construction Conference May 8, 2014 New York

Wells Fargo Securities Industrial & Construction Conference May 8, 2014 New York Wells Fargo Securities Industrial & Construction Conference May 8, 2014 New York Nick Fanandakis Chief Financial Officer E. I. du Pont de Nemours & Company Regulation G The attached charts include company

More information

LANXESS Q Financial Summary for Investors and Analysts

LANXESS Q Financial Summary for Investors and Analysts LANXESS Q3 2017 Financial Summary for Investors and Analysts Q3 2017 Overview Another strong quarter Growing organically and inorganically Q3 2017 Q3 2016 Comments Sales +25% 2,404 m 1,921 m Chemtura,

More information

Stockholders Newsletter 2004 Interim Report for the Second Quarter of 2004

Stockholders Newsletter 2004 Interim Report for the Second Quarter of 2004 Stockholders Newsletter 2004 Interim Report for the Second Quarter of 2004 TABLE OF CONTENTS Bayer Group Key Data General Business Development Performance by Subgroup Bayer HealthCare Bayer CropScience

More information

Stockholders Newsletter. Interim Report for the First Half of 2001

Stockholders Newsletter. Interim Report for the First Half of 2001 Stockholders Newsletter 2001 Interim Report for the First Half of 2001 Interim Report for the First Half Economy remains weak Extensive programs in place to improve margins Sales from Continuing Operations

More information

BASF We create chemistry. Dr. Lars Budde, Senior Manager Investor Relations EQUITA European Conference, Milan, November 23, 2017

BASF We create chemistry. Dr. Lars Budde, Senior Manager Investor Relations EQUITA European Conference, Milan, November 23, 2017 BASF We create chemistry Dr. Lars Budde, Senior Manager Investor Relations EQUITA European Conference, Milan, November 23, 2017 Cautionary note regarding forward-looking statements This presentation contains

More information

Investor Handout Q April 2012 I Leverkusen

Investor Handout Q April 2012 I Leverkusen Investor Handout Q1 2012 April 2012 I Leverkusen Science For A Better Life This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup

More information

September 18, 2014 / Marijn Dekkers, CEO

September 18, 2014 / Marijn Dekkers, CEO Transforming Bayer into a Pure Life Company - Exit of Material September 18, 2014 / Marijn Dekkers, CEO Page 1 Investor Conference Call Marijn Dekkers September 18, 2014 Disclaimer This presentation may

More information

2007 PROFORMA COMBINED FINANCIAL INFORMATION FOR AKZO NOBEL AND ICI PER QUARTER AND PER BUSINESS AREA

2007 PROFORMA COMBINED FINANCIAL INFORMATION FOR AKZO NOBEL AND ICI PER QUARTER AND PER BUSINESS AREA 2007 PROFORMA COMBINED FINANCIAL INFORMATION FOR AKZO NOBEL AND ICI PER QUARTER AND PER BUSINESS AREA Financial highlights continuing operations Millions of euros Q1 Q2 Q3 Q4 Total 2007 Revenue continuing

More information

Safe Harbour. Investor Handout Spring 2002

Safe Harbour. Investor Handout Spring 2002 Investor Handout Spring 2002 Safe Harbour This presentation contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks,

More information

Stockholders Newsletter

Stockholders Newsletter k Cover Picture Stockholders Newsletter F i n a n c i a l r e p o r t a s o f S e p t e m b e r 3 0, 2 0 1 1 After a good third quarter: Bayer confirms Group outlook Contents Interim Group management Report

More information

Working To Create Value. Version Summer 2004 Q2'04. Investor Handout. Performance Objectives Opportunities Strategy Financials

Working To Create Value. Version Summer 2004 Q2'04. Investor Handout. Performance Objectives Opportunities Strategy Financials Working To Create Value Version Summer 2004 Q2'04 Investor Handout Performance Objectives Opportunities Strategy Financials Table of Contents Safe Harbour 4 Create Value 5 Q2'04 Performance 7 Organization

More information

Record quarter for Bayer. Interim Report as of March 31, Dynamic start to 2006

Record quarter for Bayer. Interim Report as of March 31, Dynamic start to 2006 Interim Report as of March 31, Dynamic start to Record quarter for Bayer R Bayer Group Key Data R Financial Calendar R Overview of Sales, Earnings and Financial Position R Takeover Offer for Schering AG

More information

Investor Handout 1st Quarter 2002 Results

Investor Handout 1st Quarter 2002 Results Investor Handout 1st Quarter 2002 Results Safe Harbour This presentation contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and

More information

October 22, 2013 Media Contact: Patty Seif WILMINGTON, Del Investor Contact:

October 22, 2013 Media Contact: Patty Seif WILMINGTON, Del Investor Contact: October 22, 2013 Media Contact: Patty Seif WILMINGTON, Del. 302-774-4482 patricia.r.seif@dupont.com Investor Contact: 302-774-4994 DuPont Delivers 3Q 2013 Operating Earnings of $.45 per Share Sales Increase

More information

Stockholders Newsletter

Stockholders Newsletter Stockholders Newsletter Financial Report as of September 30, Bayer continues on path of growth in third quarter 8 For direct access to a chapter, simply click on its name. R Bayer Group Key Data 2 Interim

More information

Brooks Automation, Inc. 4 th Quarter Fiscal 2013 Financial Results Conference Call

Brooks Automation, Inc. 4 th Quarter Fiscal 2013 Financial Results Conference Call Brooks Automation, Inc. 4 th Quarter Fiscal 2013 Financial Results Conference Call November 14, 2013 Safe Harbor Statement Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act

More information

Three Months Ended Year Ended

Three Months Ended Year Ended DANAHER CORPORATION RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES Three Months Ended Year Ended December 31, 2014 December 31, 2013 December 31, 2014 December 31, 2013 Diluted Net Earning Per Share

More information

Reporting Factsheet. BASF Group. Segments Sales EBIT bef. special items EBIT

Reporting Factsheet. BASF Group. Segments Sales EBIT bef. special items EBIT n Reporting Factsheet Q4 2012 BASF Group (Million ) Q4 2012 Q4 2011 Change (%) Q4 2012 Q3 2012 Change (%) Sales 19,648 18,068 8.7 19,648 19,010 3.4 Income from operations before depreciation and amortization

More information

Tackling the challenges ahead

Tackling the challenges ahead Michael Heinz Chief Executive Officer & Global Integration Manager Ciba Vontobel Swiss Chemicals Day, Zurich August 27, 2009 Tackling the challenges ahead 1 1 Robust performance in difficult environment

More information

July 26, Second Quarter 2018 Earnings Presentation

July 26, Second Quarter 2018 Earnings Presentation July 26, 2018 Second Quarter 2018 Earnings Presentation Disclaimer Statement Regarding Safe Harbor For Forward-Looking Statements This presentation contains forward-looking statements, that is, information

More information

Fiscal 2018 Fourth Quarter Results. July 26, 2018

Fiscal 2018 Fourth Quarter Results. July 26, 2018 Fiscal 2018 Fourth Quarter Results July 26, 2018 Safe Harbor This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section

More information

Interim Report Second Quarter of 2017

Interim Report Second Quarter of 2017 Interim Report Second Quarter of 207 Bayer Interim Report as of June 30, 207 Key Data 2 Bayer Group Key Data million Q2 206 Q2 207 Change % H 206 H 207 Change % Full Year 206 Sales,833 2,93 + 3.0 23,687

More information

Investor Conference Call

Investor Conference Call Investor Conference Call /////////// Q2 2018 Results September 05, 2018 Werner Baumann, CEO Wolfgang Nickl, CFO Cautionary Statements Regarding Forward-Looking Information Certain statements contained

More information

Dow Reports Fourth Quarter Results Record Fourth Quarter Sales and Strong Earnings Second Highest Annual Earnings in Company s History

Dow Reports Fourth Quarter Results Record Fourth Quarter Sales and Strong Earnings Second Highest Annual Earnings in Company s History January 25, 2007 Dow Reports Fourth Quarter Results Record Fourth Quarter Sales and Strong Earnings Second Highest Annual Earnings in Company s History Fourth Quarter of Highlights Sales set a new fourth

More information

Quarterly Statement 3rd Quarter 2018 BASF Group increases sales, earnings below prior-year quarter

Quarterly Statement 3rd Quarter 2018 BASF Group increases sales, earnings below prior-year quarter Quarterly Statement 3rd Quarter 2018 BASF Group increases sales, earnings below prior-year quarter Sales grow 8% to 15.6 billion, largely driven by higher prices EBIT before special items down 14% to 1.5

More information

The Dow Chemical Company ("Dow" or the "Company")

The Dow Chemical Company (Dow or the Company) ("Dow" or the "Company") Reconciliation of non-gaap financial measures Some Dow communications or presentations to investors contain certain financial measures that are not defined under accounting principles

More information

CORNING INCORPORATED AND SUBSIDIARY COMPANIES CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited; in millions, except per share amounts)

CORNING INCORPORATED AND SUBSIDIARY COMPANIES CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited; in millions, except per share amounts) CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited; in millions, except per share amounts) For the three months ended March 31, 2005 2004 Net sales $ 1,050 $ 844 Cost of sales 621 544 Gross margin 429 300

More information

BASF with good quarterly results in the chemicals and crop protection businesses

BASF with good quarterly results in the chemicals and crop protection businesses First Quarter 2015 Financial highlights April 30, 2015 150 years BASF with good quarterly results in the chemicals and crop protection businesses Cautionary note regarding forward-looking statements 150

More information

Safe Harbor and Non-GAAP Measures

Safe Harbor and Non-GAAP Measures Safe Harbor and Non-GAAP Measures Forward-Looking Statements This presentation contains statements about future events and expectations that constitute forward-looking statements. Forward-looking statements

More information

Financial Results & Outlook for FY2012

Financial Results & Outlook for FY2012 Financial Results & Outlook for May 10, 2012 (Cautionary Statement) Statements made in this material with respect to Sumitomo Chemical s current plans, estimates, strategies and beliefs that are not historical

More information

First Quarter 2018 Financial Review and Analysis (preliminary, unaudited)

First Quarter 2018 Financial Review and Analysis (preliminary, unaudited) First Quarter 2018 Financial Review and Analysis (preliminary, unaudited) Supplemental Presentation Materials Unless otherwise indicated, comparisons are to the same period in the prior year. 1 First Quarter

More information

January 24, 2006 Contact: Clif Webb WILMINGTON, Del

January 24, 2006 Contact: Clif Webb WILMINGTON, Del January 24, 2006 Contact: Clif Webb WILMINGTON, Del. 302-774-4005 r-clifton.webb@usa.dupont.com Highlights DUPONT REPORTS FOURTH QUARTER AND FULL YEAR 2005 EARNINGS EXPECTS EARNINGS OF $2.60 PER SHARE

More information

Q Earnings Presentation August 2, 2018

Q Earnings Presentation August 2, 2018 Q2 2018 Earnings Presentation August 2, 2018 Safe Harbor Statement Safe Harbor Statement under the Private Securities Act of 1995: Statements in this news release that are forward-looking statements are

More information

VISTEON CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (Dollars in Millions, Except Per Share Data) (Unaudited)

VISTEON CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (Dollars in Millions, Except Per Share Data) (Unaudited) CONSOLIDATED STATEMENTS OF OPERATIONS (Dollars in Millions, Except Per Share Data) (Unaudited) Three Months Ended Six Months Ended June 30 June 30 2018 2017 2018 2017 Sales $ 758 $ 774 $ 1,572 $ 1,584

More information